Skip to main
CLYM

CLYM Stock Forecast & Price Target

CLYM Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Climb Bio Inc. exhibits a positive outlook driven by the significant potential of its product candidate, budoprutug, supported by a substantial increase in projected peak sales from $1.8 billion and a raised patient target due to the lack of competition in CD19 therapies. The company's strategic moves, such as the acquisition of Tenet Medicines and a successful $120 million PIPE, have bolstered its valuation, indicating strong investor confidence. Furthermore, promising clinical data from both budoprutug and CLYM116 suggest opportunities for enhanced efficacy and value appreciation, paralleling previous successes observed with similar biotechnology firms.

Bears say

Climb Bio Inc. faces a negative outlook primarily due to its history of unprofitability and the significant risks associated with the clinical development of its lead product candidates, budoprutug and CLYM116. There are concerns regarding the potential for failure to advance these candidates in clinical trials, as evidenced by the underperformance of similar therapies like rituximab, which failed to meet endpoints in critical trials. Additionally, uncertainties surrounding regulatory approvals, partnership viability, and the risk of medium- to long-term dilution further exacerbate the financial challenges facing the company.

CLYM has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Climb Bio Inc (CLYM) Forecast

Analysts have given CLYM a Buy based on their latest research and market trends.

According to 4 analysts, CLYM has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Climb Bio Inc (CLYM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.